NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/11/2022
Back to search
Official data from USPTO
MEDICAGO UNLEASH THE POWER OF PLANTS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MEDICAGO UNLEASH THE POWER OF PLANTS
ST13
US500000090620821Class
5, 40, 42, 44
Filing
90620821
Registration
6868840
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
20
Latest update
10/11/2022
Trademark type
Word
Nice classes
5, 40, 42, 44
Filing date
04/02/2021
Registration date
10/11/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/11/2022
Last transaction
10/11/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
03
Owner location
Québec (Québec), CA
Examiner
DAVIS, TRENTON
Law office
L90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Medicago Inc.
Representatives
Benjamin M. Cantor CANTOR COLBURN LLP
Technical classification
Nice Classes
Class 5Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and medicinal preparations and substanceshuman vaccinestherapeutic proteins and antibodies for the treatment of infectious diseaseschronic diseases and cancer
Class 40
Manufacture of pharmaceuticalspharmaceutical ingredientshuman vaccinestherapeutic proteins and antibodies for others; Custom manufacturing of pharmaceuticalspharmaceutical ingredientshuman vaccinestherapeutic proteins and antibodies
Class 42
Research and development in the field of human vaccinesrecombinant proteins and antibodies for therapeutic and prophylactic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccinestherapeutic proteins and antibodies; product research and development and scientific researchall in the field of protein production using recombinant technologies through transient expression in plants; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticalspharmaceutical ingredientshuman vaccinestherapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates; Medical information servicesproviding medical research information to physicianshealthcare professionals and patients on the topics of diagnosticprophylactic and therapeutic properties of vaccinesrecombinant proteins and antibodies; On-line information servicesproviding medical research information to physicianshealthcare professionals and patients on the topics of diagnosticprophylactic and therapeutic properties of vaccinesrecombinant proteins and antibodies
Class 44
Medical information servicesproviding medical information to physicianshealthcare professionals and patients on the topics of health issues and maintaining awareness of one's health; Medical information servicesproviding medical information to physicianshealthcare professionals and patients on the topics of diagnosticprophylactic and therapeutic properties of vaccinesrecombinant proteins and antibodies; On-line information servicesproviding medical information to physicianshealthcare professionals and patients on the topics of health issues and maintaining awareness of one's health; On-line information servicesproviding medical information to physicianshealthcare professionals and patients on the topics of diagnosticprophylactic and therapeutic properties of vaccinesrecombinant proteins and antibodies
Publications
History of USPTO decisions and trademark events.
20 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
10/11/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/26/2022
PUBO
PUBLISHED FOR OPPOSITION
07/26/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/06/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/23/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
06/22/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/22/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
06/22/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/22/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/02/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/02/2022
ALIE
ASSIGNED TO LIE
06/02/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/25/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/26/2021
GNRT
NON-FINAL ACTION E-MAILED
11/26/2021
CNRT
NON-FINAL ACTION WRITTEN
11/26/2021
DOCK
ASSIGNED TO EXAMINER
11/17/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/11/2021
NWAP
NEW APPLICATION ENTERED
04/06/2021
Continuous trademark protection
Get notified about every new filing that threatens MEDICAGO UNLEASH THE POWER OF PLANTS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.